Human SARS-CoV-2 Nucleocapsid IgG (SARS-CoV-2 N IgG) ELISA Kit |
|
abx395203-100l |
Abbexa |
100 µl |
EUR 687.5 |
Human IgG antibody Laboratories manufactures the the sars-cov kit diagnosis reagents distributed by Genprice. The The Sars-Cov Kit Diagnosis reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Kit. Other The products are available in stock. Specificity: The Category: Sars-Cov Group: Kit Diagnosis
Human SARS-CoV-2 N IgG Antibody ELISA Kit |
|
Cusabio |
96Т |
EUR 595 |
|
|
|
Description: serum, plasma |
Human SARS-CoV-2 N IgG Antibody ELISA Kit |
|
Cusabio |
48T |
EUR 290.06 |
|
|
|
Description: Homo sapiens (Human) |
Human SARS-CoV-2 N IgG Antibody ELISA Kit |
|
Cusabio |
96T |
EUR 446.25 |
|
|
|
Description: Homo sapiens (Human) |
Human SARS-CoV-2 IgM/IgG ELISA Kit |
|
EnoGene |
N/A |
Ask for price |
|
Description: N/A |
SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody |
|
Abbexa |
100 tests |
EUR 1237.5 |
SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody |
|
Abbexa |
100 tests |
EUR 1237.5 |
SARS-CoV-2 Human IgG Assay Control |
|
Genovis AB |
1 mL |
EUR 105 |
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit |
|
Biovision |
96 assays |
EUR 1268.4 |
SARS-CoV-2 IgG/IgM Antibody ELISA Kit |
|
Abclonal |
96T |
EUR 467.61 |
SARS-COV-2 IgG ELISA Kit (Quantitative) |
|
Creative Diagnostics |
96T |
EUR 1039.92 |
|
Description: Serum, plasma |
*SARS-CoV-2 IgG Seroconversion ELISA Kit |
|
Innovative research |
each |
EUR 198 |
|
|
|
Description: *SARS-CoV-2 IgG Seroconversion ELISA Kit |
Kit Diagnosis information
SARS-CoV-2 NSP10/NSP16 Methyltransferase, Active |
|
REC31938-20 |
The Native Antigen Company |
0.02 |
EUR 545.93 |
|
Description: Recombinant SARS-CoV-2 NSP10/NSP16 methyltransferase includes full length NSP10 and NSP16 expressed in E. coli using C-terminal His tag. |
SARS-CoV-2 NSP10/NSP16 Methyltransferase, Active |
|
REC31938-50 |
The Native Antigen Company |
0.05 |
EUR 775.11 |
|
Description: Recombinant SARS-CoV-2 NSP10/NSP16 methyltransferase includes full length NSP10 and NSP16 expressed in E. coli using C-terminal His tag. |
SARS-CoV-2 Nucleoprotein, His-Tag (E. coli) |
|
REC31851-100 |
The Native Antigen Company |
0.1 |
EUR 427.47 |
|
|
|
Description: Recombinant SARS-CoV-2 full-length nucleoprotein, expressed and purified from E. coli with a 6xHis-tag. |
SARS-CoV-2 Nucleoprotein, His-Tag (E. coli) |
|
REC31851-1000 |
The Native Antigen Company |
1 |
EUR 2770.83 |
|
|
|
Description: Recombinant SARS-CoV-2 full-length nucleoprotein, expressed and purified from E. coli with a 6xHis-tag. |
SARS-CoV-2 Nucleoprotein, His-Tag (E. coli) |
|
REC31851-500 |
The Native Antigen Company |
0.5 |
EUR 1628.77 |
|
|
|
Description: Recombinant SARS-CoV-2 full-length nucleoprotein, expressed and purified from E. coli with a 6xHis-tag. |
SARS-CoV-2 3C-Like Proteinase (3CLpro), Active |
|
REC31875-20 |
The Native Antigen Company |
0.02 |
EUR 588.42 |
|
Description: Recombinant full-length 2019-nCoV 3CLpro, part of the large replicase polyprotein 1ab (S3264-Q3569), expressed in E. coli cells with an N-terminal His-tag. |
SARS-CoV-2 3C-Like Proteinase (3CLpro), Active |
|
REC31875-50 |
The Native Antigen Company |
0.05 |
EUR 830.48 |
|
Description: Recombinant full-length 2019-nCoV 3CLpro, part of the large replicase polyprotein 1ab (S3264-Q3569), expressed in E. coli cells with an N-terminal His-tag. |
SARS-CoV-2 Papain-Like Protease (PLpro), Active |
|
REC31873-20 |
The Native Antigen Company |
0.02 |
EUR 602.58 |
|
Description: Recombinant SARS-CoV-2 papain-like protease (PLpro), part of the large replicase polyprotein 1ab (E1564-Y1882), expressed in E. coli cells with an N-terminal His-tag. |
SARS-CoV-2 Papain-Like Protease (PLpro), Active |
|
REC31873-50 |
The Native Antigen Company |
0.05 |
EUR 860.09 |
|
Description: Recombinant SARS-CoV-2 papain-like protease (PLpro), part of the large replicase polyprotein 1ab (E1564-Y1882), expressed in E. coli cells with an N-terminal His-tag. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (JB8) |
|
MAB12466-100 |
The Native Antigen Company |
0.1 |
EUR 281.98 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (JB8) |
|
MAB12466-500 |
The Native Antigen Company |
0.5 |
EUR 701.72 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (JA6) |
|
MAB12467-100 |
The Native Antigen Company |
0.1 |
EUR 281.98 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (JA6) |
|
MAB12467-500 |
The Native Antigen Company |
0.5 |
EUR 701.72 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (JF1) |
|
MAB12468-100 |
The Native Antigen Company |
0.1 |
EUR 281.98 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (JF1) |
|
MAB12468-500 |
The Native Antigen Company |
0.5 |
EUR 701.72 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (GC12) |
|
MAB12465-100 |
The Native Antigen Company |
0.1 |
EUR 281.98 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
Mouse Anti SARS-CoV-2 Nucleoprotein Antibody (GC12) |
|
MAB12465-500 |
The Native Antigen Company |
0.5 |
EUR 701.72 |
|
Description: Mouse monoclonal antibody against SARS-CoV-2 nucleoprotein. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (L14) |
|
MAB12473-100 |
The Native Antigen Company |
0.1 |
EUR 727.47 |
|
Description: Recombinant Llama VHH Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD , Spike protein RBD (N501Y) variant, and triple mutant (K417N, E484K, N501Y) RBD. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (L14) |
|
MAB12473-20 |
The Native Antigen Company |
0.02 |
EUR 370.82 |
|
Description: Recombinant Llama VHH Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD , Spike protein RBD (N501Y) variant, and triple mutant (K417N, E484K, N501Y) RBD. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (L25) |
|
MAB12474-100 |
The Native Antigen Company |
0.1 |
EUR 727.47 |
|
Description: Recombinant Llama VHH Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (L25) |
|
MAB12474-20 |
The Native Antigen Company |
0.02 |
EUR 370.82 |
|
Description: Recombinant Llama VHH Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (L38) |
|
MAB12475-100 |
The Native Antigen Company |
0.1 |
EUR 727.47 |
|
Description: Recombinant Llama VHH Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD and RBD (N501Y) variants. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (L38) |
|
MAB12475-20 |
The Native Antigen Company |
0.02 |
EUR 370.82 |
|
Description: Recombinant Llama VHH Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD and RBD (N501Y) variants. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (HL14) |
|
MAB12469-100 |
The Native Antigen Company |
0.1 |
EUR 727.47 |
|
Description: Recombinant Llama VHH-Human IgG Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD and Spike protein RBD (N501Y) variant. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (HL14) |
|
MAB12469-20 |
The Native Antigen Company |
0.02 |
EUR 370.82 |
|
Description: Recombinant Llama VHH-Human IgG Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD and Spike protein RBD (N501Y) variant. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (HL25) |
|
MAB12470-100 |
The Native Antigen Company |
0.1 |
EUR 727.47 |
|
Description: Recombinant Llama VHH-Human IgG Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (HL25) |
|
MAB12470-20 |
The Native Antigen Company |
0.02 |
EUR 370.82 |
|
Description: Recombinant Llama VHH-Human IgG Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD. |
SARS-CoV-2 Spike Protein Neutralizing Nanobody (HL38) |
|
MAB12471-100 |
The Native Antigen Company |
0.1 |
EUR 727.47 |
|
Description: Recombinant Llama VHH-Human IgG Antibody for studying neutralization of SARS-CoV-2 and detection of Spike glycoprotein. Neutralizing activity validated for wild type Spike protein RBD and Spike protein RBD (N501Y) variant. |
